Spots Global Cancer Trial Database for esophageal squamous cell carcinoma
Every month we try and update this database with for esophageal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma | NCT02399306 | Esophageal Squa... Enteral Nutriti... Chemoradiothera... | Enteral nutriti... radiotherapy | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy | NCT04199832 | Esophageal Squa... Chemoradiothera... Enteral Nutriti... | Dietary guidanc... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma | NCT04054518 | Esophageal Squa... | Durvalumab | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer | NCT05880082 | Esophageal Squa... | Tislelizumab | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04435197 | Esophageal Squa... | Pembrolizumab I... | 18 Years - 75 Years | Ruijin Hospital | |
| TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma | NCT06401447 | Esophageal Squa... | Radiotherapy | 18 Years - 80 Years | Fudan University | |
| Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | NCT04229459 | Esophageal Squa... | Cisplatin 5-FU Radiation thera... Cetuximab Nivolumab | 18 Years - | Rabin Medical Center | |
| S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | NCT05312372 | Esophageal Squa... | Combination (S0... | 18 Years - | Servier | |
| Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin | NCT03273647 | Esophageal Squa... Positive Circum... | radiation | 18 Years - 18 Years | Fudan University | |
| Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. | NCT06020885 | Esophageal Squa... | Split-course hy... Induction chemo... Concurrent chem... | 18 Years - 80 Years | Sun Yat-sen University | |
| Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | NCT02123381 | Locally Advance... | preoperative ra... cetuximab | 18 Years - 65 Years | Sichuan Cancer Hospital and Research Institute | |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | NCT03603756 | Esophageal Squa... | SHR-1210 Apatinib Irinotecan Inje... Paclitaxel lipo... Nedaplatin | 18 Years - 70 Years | ChineseAMS | |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | NCT05563766 | Esophageal Aden... Esophageal Squa... Gastroesophagea... | Itraconazole | 18 Years - | VA Office of Research and Development | |
| Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | NCT03888092 | Esophageal Squa... | Z650 | 18 Years - 75 Years | Sunshine Lake Pharma Co., Ltd. | |
| NCI UNC Project ESCC | NCT03206125 | Esophageal Squa... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | NCT05348668 | Esophageal Squa... | Hybrid dose-fra... | 18 Years - 75 Years | Anhui Provincial Hospital | |
| Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | NCT02844075 | Esophageal Squa... | MK-3475(pembrol... | 20 Years - | Yonsei University | |
| Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma | NCT05978193 | Esophageal Squa... Esophageal Canc... Metastatic Esop... | LDRT+CFRT Immunotherapy Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
| Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC | NCT04759235 | Esophageal Squa... | Magnetic resona... 18F-Fluorodeoxy... Blood and urine... | 18 Years - 75 Years | RenJi Hospital | |
| A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | NCT06010303 | Esophageal Canc... Esophageal Squa... Esophageal Squa... | LBL-007 Tislelizumab Chemotherapy Do... | 18 Years - | BeiGene | |
| Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years | NCT05604950 | Esophageal Squa... Esophagectomy Radiotherapy Chemotherapy | Since the data ... | 70 Years - 100 Years | Sichuan Cancer Hospital and Research Institute | |
| Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | NCT03987815 | Esophageal Squa... | Nivolumab | 19 Years - | Samsung Medical Center | |
| Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia | NCT02047305 | ESOPHAGEAL SQUA... | Radiofrequency ... | 18 Years - 80 Years | Medtronic - MITG | |
| Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | NCT05990231 | Esophageal Squa... | Cadonilimab com... | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma | NCT02913066 | Esophageal Squa... | S-1 concurrent ... S-1 plus Cispla... | - 75 Years | Mianyang Central Hospital | |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | NCT04390958 | Esophageal Squa... | nab-paclitaxel Cisplatin Capecitabine | 18 Years - 75 Years | ChineseAMS | |
| A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | NCT01591135 | Esophageal Squa... | Paclitaxel plus... Cisplatin plus ... Radiation thera... Radiation thera... | 18 Years - 75 Years | Fudan University | |
| HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi | NCT03160209 | Esophageal Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Precisely Estimation of the Prognostic Value of Lymph Node in ESCC | NCT04764240 | Esophageal Squa... | R0 resection wi... | 18 Years - | Shanghai Cancer Hospital, China | |
| Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | NCT05740995 | Esophageal Squa... Neoadjuvant Che... | neoadjuvant ant... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma | NCT05028725 | Esophageal Squa... Esophageal Squa... | EsophaCap Spong... Chromoendoscopy EsoCAN assay | 18 Years - | University of California, San Francisco | |
| Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy | NCT01402180 | Esophageal Squa... | Nimotuzumab Radiation thera... radiation thera... chemotherapy chemotherapy | 18 Years - 75 Years | Fudan University | |
| Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | NCT02350517 | Esophageal Squa... | Paclitaxel+Neda... | 18 Years - 75 Years | Sun Yat-sen University | |
| Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | NCT03985046 | Esophageal Squa... | Sintilimab plus... | 18 Years - 75 Years | Fudan University | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus | NCT03792347 | Esophageal Squa... | Pembrolizumab | 18 Years - 75 Years | Ruijin Hospital | |
| A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | NCT01608022 | Esophageal Squa... | PF804 | 20 Years - | Yonsei University | |
| Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | NCT05174325 | Esophageal Squa... | Sintilimab + ch... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC | NCT04973306 | Esophageal Squa... Esophageal Squa... | Neoadjuvant Che... Tislelizumab Ivor-Lewis or M... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | NCT05044728 | Non-small Cell ... Esophageal Squa... | Anti-PD-1 antib... Surgical treatm... | 18 Years - 72 Years | Sichuan Cancer Hospital and Research Institute | |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | NCT03766178 | Esophageal Squa... | Nimotuzumab + S... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | NCT05302011 | Esophageal Squa... | Pembrolizumab Carboplatin or ... Docetaxel | 18 Years - | Peking Union Medical College Hospital | |
| Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | NCT04009265 | Esophageal Squa... | adjuvant treatm... | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | NCT06184841 | Hepatic Arteria... Liver Metastase... Esophageal Squa... | HAIC combined w... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma | NCT02969473 | Esophageal Neop... Chemoradiation | Docetaxel Fluorouracil | 18 Years - 70 Years | Sun Yat-sen University | |
| Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | NCT05174325 | Esophageal Squa... | Sintilimab + ch... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| RAPA-201 Therapy of Solid Tumors | NCT05144698 | Solid Tumor Breast Cancer Small Cell and ... Triple Negative... Gastric Cancer Esophageal Aden... Gastric Junctio... Esophageal Squa... Head and Neck C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Carcinoma of Un... Bladder Cancer Malignant Melan... | RAPA-201 Rapamy... Chemotherapy Pr... | 18 Years - | Rapa Therapeutics LLC | |
| Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | NCT05984342 | Esophageal Squa... | Tislelizumab | 18 Years - 70 Years | Affiliated Cancer Hospital of Shantou University Medical College | |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients | NCT01258192 | Esophageal Squa... | albumin-bound p... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | NCT06048926 | Esophageal Squa... | Carrelizumab Paclitaxel inje... Cisplatin Concurrent chem... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Endoscopic Screening on Esophageal Cancer | NCT02094105 | Esophageal Squa... | Endoscopy exami... | 40 Years - 69 Years | ChineseAMS | |
| A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya | NCT00901173 | Esophageal Squa... | 7 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients | NCT05170256 | Esophageal Squa... HER-2 Protein O... HER-2 Gene Ampl... | Trastuzumab | 18 Years - | Rigshospitalet, Denmark | |
| Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | NCT04699994 | Esophageal Squa... | FLOT therapy | 20 Years - | Keio University | |
| Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma | NCT04380480 | Esophageal Squa... | Concurrent chem... | 18 Years - 75 Years | Sun Yat-sen University | |
| Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237） | NCT05980403 | Esophageal Squa... | no intervention | - | Renmin Hospital of Wuhan University | |
| The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers | NCT02435602 | Esophageal Squa... Squamous Cell C... | NBI endoscopy Lugol chromoend... | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) | NCT04138212 | Esophageal Squa... | Paclitaxel, Cis... neoadjuvant che... | 18 Years - 70 Years | Henan Cancer Hospital | |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT06304974 | Esophageal Squa... | BL-B01D1 Irinotecan paclitaxel docetaxel | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer | NCT03474341 | Esophageal Canc... Esophageal Aden... Esophageal Squa... Esophageal Neop... | MRI PET-CT Endoscopy Blood samples | 18 Years - | UMC Utrecht | |
| A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | NCT06194734 | Esophageal Squa... | KC1036 Irinotecan Docetaxel S-1 | 18 Years - 75 Years | Beijing Konruns Pharmaceutical Co., Ltd. | |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | NCT06056336 | Esophageal Squa... Neoadjuvant Che... Adjuvant Therap... | Tislelizumab | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Esophageal cAncer Screening Trial | NCT04609813 | Esophageal Squa... Esophageal Canc... Gastroesophagea... | Sponge cytologi... | 40 Years - 75 Years | Changhai Hospital | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) | NCT05520619 | Esophageal Squa... Locally Advance... | Paclitaxel, Cis... tislelizumab Radiotherapy | 18 Years - 70 Years | Sun Yat-sen University | |
| Esophageal Cytology With FISH in Detecting Esophageal Cancer | NCT02100189 | Dysphagia Dysplasia Esophageal Aden... Esophageal Squa... Esophagitis Gastroesophagea... High Grade Dysp... Weight Loss | Cytology Specim... Esophagogastrod... Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT04229849 | Esophageal Squa... | Anrotenib plus ... Toripalimab | 18 Years - | Henan Cancer Hospital | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer | NCT03377400 | Esophageal Squa... | Durvalumab | 19 Years - | Samsung Medical Center | |
| Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | NCT06048926 | Esophageal Squa... | Carrelizumab Paclitaxel inje... Cisplatin Concurrent chem... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | NCT03925870 | Esophageal Squa... | KN046 | 18 Years - 75 Years | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04177797 | Esophageal Squa... | Toripalimab | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT03964753 | Esophageal Squa... | Nab-paclitaxel ... surgery | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer | NCT01551589 | Esophageal Squa... | Involved Field ... docetaxel and c... Elective Nodal ... | 18 Years - 80 Years | The Second People's Hospital of Sichuan | |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) | NCT06187597 | Locally Advance... | S-1 Toripalimab Intensity-modul... | 70 Years - 85 Years | Sun Yat-sen University | |
| Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction | NCT04224363 | Esophageal Squa... | staining from c... staining from e... | 18 Years - 80 Years | Shandong University | |
| CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer | NCT04481100 | Esophageal Neop... Esophageal Dise... Esophageal Squa... | itraconazole | 18 Years - 75 Years | Hangzhou Cancer Hospital | |
| Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC | NCT04514822 | Esophageal Squa... Positron Emissi... | Dynamic PET | 18 Years - 85 Years | Fifth Affiliated Hospital, Sun Yat-Sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
